$39.90
Sermorelin for sale for laboratory research — sermorelin (GRF 1-29) is the 29-amino-acid N-terminal fragment of human growth hormone-releasing hormone (GHRH), retaining the full receptor activity of the native 44-amino-acid hormone, supplied lyophilized at ≥99% purity.
Sermorelin is the shortest fully active fragment of GHRH, developed as sermorelin acetate (Geref). Mechanism: it binds the GHRH receptor on anterior pituitary somatotrophs, stimulating the synthesis and pulsatile release of endogenous growth hormone. Because it works upstream of the pituitary, secretion in research models remains subject to somatostatin negative feedback — preserving physiological pulsatility, in contrast to exogenous growth hormone administration. Its half-life is short, in the range of 10–20 minutes, with downstream GH and IGF-1 effects persisting well beyond clearance.
Sermorelin was FDA-approved as Geref for the diagnosis and treatment of pediatric growth hormone deficiency before being discontinued in 2008 for commercial rather than safety reasons — leaving an unusually deep human research record for a peptide in this class. Research interest centres on GH-axis function, the age-related decline in GH secretion (somatopause), sleep-associated GH pulse amplitude, and body-composition endpoints in GHRH-axis models.
CJC-1295 without DAC (Mod GRF 1-29) is a four-substitution analog of sermorelin engineered for greater stability and a longer half-life, making sermorelin the reference compound in GHRH-analog comparison studies. In research protocols, GHRH fragments are frequently combined with ghrelin-mimetic GHRPs — as in the CJC-1295 + Ipamorelin GH stack — where the two receptor pathways act synergistically on GH pulse amplitude.
VMAX sermorelin is supplied as a lyophilized research peptide verified to ≥99% purity by HPLC and mass spectrometry, available in multiple vial sizes selectable on this page.
Handling: Lyophilized peptide. Store sealed at -20°C for long-term stability or 2-8°C short-term. Reconstitute with bacteriostatic water. After reconstitution, store at 2–8°C and avoid repeated freeze-thaw cycles.
For research purposes only. Not for human consumption. This material is intended exclusively for in-vitro laboratory and preclinical research applications conducted by qualified personnel.
Sermorelin is the 29-amino-acid N-terminal fragment of growth hormone-releasing hormone (GHRH), retaining the full biological activity of the native hormone and studied for its stimulation of endogenous growth hormone release.
Sermorelin is supplied as a lyophilized research compound verified to ≥99% purity by HPLC and mass spectrometry.
Store the lyophilized peptide sealed at -20°C for long-term stability, or 2–8°C short-term. After reconstitution, store at 2–8°C and avoid repeated freeze-thaw cycles.
CJC-1295 without DAC is a modified version of sermorelin with four amino-acid substitutions that increase stability and half-life, while sermorelin is the unmodified native GHRH(1-29) fragment used as the reference compound in comparison research.
No. This material is sold strictly for in-vitro laboratory and preclinical research by qualified personnel. It is not for human or veterinary use.
Sermorelin is available in multiple vial sizes — select your preferred option on this product page.
| Volume | 10mg, 5mg |
|---|
Reviews
There are no reviews yet.